Q-omics provides the consensus-scored MIR506 profile across patient tissues and cancer cell-line models. MIR506 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, MIR506 is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, MIR506 RNA expression shows 5,988 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight LIHC, KIRC, and KIRP as cancer lineages where MIR506 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR506 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR506 survival associations across molecular data types. MIR506 RNA expression shows survival associations in the most cancer types (8), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR506 RNA expression–survival associations across cancer types. High MIR506 expression shows unfavorable associations in LIHC, LUAD, LGG and BRCA, but favorable associations in KIRP and KIRC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for MIR506 RNA expression.
This table summarizes MIR506 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR506. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR506 shows higher tumor expression in KIRC. The KIRC box plot shows higher MIR506 RNA expression in tumor versus normal tissue (log2 FC = +0.261, t-test p < 0.001).
This table shows molecular features associated with MIR506 in patient tissues and cancer cell lines. In patient samples, MIR506 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
